Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Proof Of Concept, Open Label, Study To Evaluate The Efficacy Of Belantamab Mafodotin In Combination With Standard Background Therapy In Patients With Previously Treated Systemic Lupus Erythematosus

NCT07844200 is registered in ClinicalTrials.gov with Medical Association for the Study of Cancer Biology and Treatment as lead sponsor.

NCT NCT07844200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07844200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Proof Of Concept, Open Label, Study To Evaluate The Efficacy Of Belantamab Mafodotin In Combination With Standard Background Therapy In Patients With Previously Treated Systemic Lupus Erythematosus
Lead sponsor
Medical Association for the Study of Cancer Biology and Treatment
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 28, 2027
Completion date
December 31, 2031
Enrollment
12 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sle - systemic lupus erythematosus